remdesivir

Health & Safety

Remdesivir Distribution Causes Confusion, Leaves Some Hospitals Empty-Handed

11:12am May 14, 2020

by Sydney Lupkin

Gilead Sciences is donating its initial supply of the experimental treatment for COVID-19. The federal government is deciding where the scarce medicine goes, and there are questions about the choices.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.

Health & Safety

Putting A Price On COVID-19 Treatment Remdesivir

11:01am May 08, 2020

by Sydney Lupkin

Gilead Sciences has committed to donating the initial supply of the experimental antiviral drug. But executives said the company will need to make expanded production of the treatment sustainable.

Gilead Sciences CEO Daniel O'Day speaks at a meeting with President Trump and members of the White House coronavirus task force on March 2.

Gilead Lobbying Rose As Interest In COVID-19 Treatment Climbed

11:51am May 02, 2020

by Sydney Lupkin

On Friday, the Food and Drug Administration authorized emergency use of remdesivir for patients with severe cases of COVID-19. Drugmaker Gilead Sciences' lobbying hit a new high in the first quarter.

Preliminary results of a study of the antiviral drug remdesivir show it is effective in shortening the recovery time for patients with COVID-19.

Health & Safety

Antiviral Drug Remdesivir Shows Promise For Treating Coronavirus In NIH Study

10:00pm April 29, 2020

The preliminary results showed that hospitalized patients who received remdesivir recovered 31% faster. Dr. Anthony Fauci hailed the findings as "quite good news."

Science

Promising Drug On The Horizon For COVID-19

7:10pm April 06, 2020

by Joe Palca

A drug that's been tested against the coronaviruses that cause MERS and SARS and shown to have valuable antiviral properties appears to be potent against the COVID-19 virus as well.

After the Food and Drug Administration granted Gilead Sciences orphan drug status for its experimental drug remdesivir on Tuesday, Gilead asked that the agency rescind that status Wednesday.

Gilead Declines 'Rare Disease' Status For Experimental Coronavirus Drug

7:30pm March 25, 2020

by Sydney Lupkin

By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and seven years without generic competition for remdesivir, its experimental COVID-19 treatment.

Gilead Sciences CEO Daniel O'Day (center) took part in a meeting of the White House Coronavirus Task Force on March 2.

FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments

7:26pm March 24, 2020

by Sydney Lupkin

Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration.